• 1
    Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 2008; 39: 115763.
  • 2
    Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 38090.
  • 3
    Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip-fractures. BMJ 1993; 307: 124850.
  • 4
    Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002; 17: 123744.
  • 5
    Reginster JY, Gillet P, Gosset C. Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health Organ 2001; 79: 9426.
  • 6
    Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E, et al. Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 2011; 22: 68592.
  • 7
    Maravic M, Taupin P, Landais P, Roux C. Change in hip fracture incidence over the last 6 years in France. Osteoporos Int 2011; 22: 797801.
  • 8
    Guilley E, Chevalley T, Herrmann F, Baccino D, Hoffmeyer P, Rapin CH, et al. Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int 2008; 19: 17417.
  • 9
    Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Jarvinen M. Nationwide decline in incidence of hip fracture. J Bone Miner Res 2006; 21: 18368.
  • 10
    Giversen IM. Time trends of age-adjusted incidence rates of first hip fractures: a register-based study among older people in Viborg County, Denmark, 1987-1997. Osteoporos Int 2006; 17: 55264.
  • 11
    Leslie WD, O'Donnell S, Jean S, Lagace C, Walsh P, Bancej C, et al. Trends in hip fracture rates in Canada. JAMA 2009; 302: 8839.
  • 12
    Chevalley T, Guilley E, Herrmann FR, Hoffineyer P, Rapin CH, Rizzoli R. Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 2007; 40: 12849.
  • 13
    Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 2011; 22: 127788.
  • 14
    Dodds MK, Codd MB, Looney A, Mulhall KJ. Incidence of hip fracture in the Republic of Ireland and future projections: a population-based study. Osteoporos Int 2009; 20: 210510.
  • 15
    Abrahamsen B, Vestergaard P. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporosis Int 2010; 21: 37380.
  • 16
    Jaglal SB, Weller I, Mamdani M, Hawker G, Kreder H, Jaakkimainen L, et al. Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Min Res 2005; 20: 898905.
  • 17
    Fisher A, Martin J, Srikusalanukul W, Davis M. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 2010; 5: 35562.
  • 18
    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009; 302: 15739.
  • 19
    Federal Planning Bureau (FBP), SPF Economy–Directorate-general Statistics and Economic information (DSE). Belgian population on January 1st, 2000-2007: observations, DSE. 2008-2061: population projections 2007-2060, FPB-DSE. URL:–34265.xls.
  • 20
    Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008; 90: 21428.
  • 21
    Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19: 8118.
  • 22
    Hiligsmann M, Rabenda V, Bruyere O, Reginster JY. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 2010; 96: 1707.
  • 23
    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399428.
  • 24
    Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 12549.
  • 25
    Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27: 58590.
  • 26
    Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34: 195202.
  • 27
    Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, et al. A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 2011; 22: 45361.
  • 28
    Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyere O, et al. A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 2009; 64: 6129. In French.
  • 29
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell O, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004; 15: 1759.
  • 30
    Chapurlat RD, Bauer DC, Nevitt M, Stone K, Cummings SR. Incidence and risk factors for a second hip fracture in elderly women: the Study of Osteoporotic Fractures. Osteoporos Int 2003; 14: 1306.
  • 31
    Berry SD, Samelson EJ, Hannan MT, McLean RR, Lu M, Cupples LA, et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med 2007; 167: 19716.
  • 32
    Colon-Emeric CS, Sloane R, Hawkes WG, Magaziner J, Zimmerman SI, Pieper CF, et al. The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 2000; 109: 3246.
  • 33
    Colon-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, et al. Clinical risk factors for recurrent fracture after hip fracture: a prospective study. Calcif Tissue Int 2011; 88: 42531.
  • 34
    Hiligsmann M, Gathon HJ, Bruyere O, Daubie M, Dercq JP, Parmentier Y, et al. Hospitalisation costs of hip fractures in Belgium [abstract]. Osteoporos Int 2011; 22: S332.
  • 35
    Melton LJ III, Kearns AE, Atkinson EJ, Bolander ME, Achenbach SJ, Huddleston JM, et al. Secular trends in hip fracture incidence and recurrence. Osteoporos Int 2009; 20: 68794.
  • 36
    Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, et al, for the Swedish Hip Fracture Study Group. Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ 1998; 316: 185863.
  • 37
    Michaelsson K, Baron JA, Johnell O, Persson I, Ljunghall S, for the Swedish Hip Fracture Study Group. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Osteoporos Int 1998; 8: 5406.
  • 38
    Hoidrup S, Gronbaek M, Pedersen AT, Lauritzen JB, Gottschau A, Schroll M. Hormone replacement therapy and hip fracture risk: effect modification by tobacco smoking, alcohol intake, physical activity, and body mass index. Am J Epidemiol 1999; 150: 108593.
  • 39
    MacLennan AH, Gill TK, Broadbent JL, Taylor AW. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009; 12: 12230.
  • 40
    Menon U, Burnell M, Sharma A, Gentry-Maharaj A, Fraser L, Ryan A, et al. Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause 2007; 14: 4627.
  • 41
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327: 163742.
  • 42
    Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007; 92: 141523.